Henan Lingrui Pharmaceutical Co Ltd
SSE:600285
Intrinsic Value
Henan Lingrui Pharmaceutical Co., Ltd. engages in the production and sale of medicine and health products. [ Read More ]
The intrinsic value of one
Henan Lingrui Pharmaceutical Co Ltd
stock under the Base Case scenario is
21.28
CNY.
Compared to the current market price of 25.45 CNY,
Henan Lingrui Pharmaceutical Co Ltd
is
Overvalued by 16%.
Henan Lingrui Pharmaceutical Co Ltd's market capitalization is 14.2B CNY.
Henan Lingrui Pharmaceutical Co Ltd stock price is 25.45 CNY.
Henan Lingrui Pharmaceutical Co Ltd stock (21.28 CNY) is 16% less than its price (25.45 CNY).
Henan Lingrui Pharmaceutical Co Ltd stock (23.08 CNY) is 9% less than its price (25.45 CNY). Open DCF Valuation
Henan Lingrui Pharmaceutical Co Ltd stock (19.48 CNY) is 23% less than its price (25.45 CNY). Open Relative Valuation
Henan Lingrui Pharmaceutical Co Ltd has downside potential of 54% compared to the average analyst price target.
Open Wall St Estimates
Henan Lingrui Pharmaceutical Co Ltd's Revenue has grown by 11% over the past 12 months.
Henan Lingrui Pharmaceutical Co Ltd's ROIC (Return on Invested Capital) has increased in the last 3 years from 12% to 16%.
Henan Lingrui Pharmaceutical Co Ltd's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 16%.
Henan Lingrui Pharmaceutical Co Ltd has positive Operating Income for the last twelve months.
Henan Lingrui Pharmaceutical Co Ltd has positive Net Income for the last twelve months.
Henan Lingrui Pharmaceutical Co Ltd has positive three-year average ROIC (Return on Invested Capital): 13%. The company is efficient at using invested capital to generate operating income.
Henan Lingrui Pharmaceutical Co Ltd's ROE (Return on Equity) has increased in the last 3 years from 15% to 20%.
Henan Lingrui Pharmaceutical Co Ltd's short-term assets (2B CNY) exceed its short-term liabilties (2B CNY).
Henan Lingrui Pharmaceutical Co Ltd's ROE (Return on Equity) for the past 12 months is positive and is equal to 20%.
Henan Lingrui Pharmaceutical Co Ltd's Revenue is forecast to grow at a rate of 14% per year over the next 3 years.
Henan Lingrui Pharmaceutical Co Ltd's Revenue has been growing by 13% per year for the last 3 years.
Henan Lingrui Pharmaceutical Co Ltd has positive three-year average ROE (Return on Equity): 17%. The company is efficient at transforming stockholders' equity into net income.
Henan Lingrui Pharmaceutical Co Ltd's long-term assets (5B CNY) exceed its long-term liabilties (2B CNY).
Henan Lingrui Pharmaceutical Co Ltd has positive Gross Profit for the last twelve months.
Henan Lingrui Pharmaceutical Co Ltd has positive Free Cash Flow for the last twelve months.
Henan Lingrui Pharmaceutical Co Ltd's D/E (Debt to Equity) is very low and is equal to 0.04.
Henan Lingrui Pharmaceutical Co Ltd has negative Net Debt. This means that the company has more cash and short-term investments (1B CNY) than debt (108m CNY).
Henan Lingrui Pharmaceutical Co Ltd's Altman Z-Score is very high and is equal to 4.63.
Valuation Backtest
Henan Lingrui Pharmaceutical Co Ltd
Run backtest to discover the historical profit from buying and selling
Henan Lingrui Pharmaceutical Co Ltd
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Henan Lingrui Pharmaceutical Co Ltd
Balance Sheet Decomposition
Henan Lingrui Pharmaceutical Co Ltd
| Current Assets | 2.4B |
| Cash & Short-Term Investments | 1.2B |
| Receivables | 657.6m |
| Other Current Assets | 570.7m |
| Non-Current Assets | 2.2B |
| Long-Term Investments | 362.2m |
| PP&E | 659.5m |
| Intangibles | 241.9m |
| Other Non-Current Assets | 922m |
| Current Liabilities | 1.8B |
| Accounts Payable | 75m |
| Accrued Liabilities | 142.4m |
| Short-Term Debt | 101.8m |
| Other Current Liabilities | 1.5B |
| Non-Current Liabilities | 82.6m |
| Long-Term Debt | 6.1m |
| Other Non-Current Liabilities | 76.5m |
Earnings Waterfall
Henan Lingrui Pharmaceutical Co Ltd
|
Revenue
|
3.2B
CNY
|
|
Cost of Revenue
|
-903.2m
CNY
|
|
Gross Profit
|
2.3B
CNY
|
|
Operating Expenses
|
-1.8B
CNY
|
|
Operating Income
|
552m
CNY
|
|
Other Expenses
|
-25.8m
CNY
|
|
Net Income
|
526.2m
CNY
|
Free Cash Flow Analysis
Henan Lingrui Pharmaceutical Co Ltd
Profitability Score
Profitability Due Diligence
Henan Lingrui Pharmaceutical Co Ltd's profitability score is 65/100. The higher the profitability score, the more profitable the company is.
Score
Henan Lingrui Pharmaceutical Co Ltd's profitability score is 65/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Henan Lingrui Pharmaceutical Co Ltd's solvency score is 76/100. The higher the solvency score, the more solvent the company is.
Score
Henan Lingrui Pharmaceutical Co Ltd's solvency score is 76/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Henan Lingrui Pharmaceutical Co Ltd
According to Wall Street analysts, the average 1-year price target for
Henan Lingrui Pharmaceutical Co Ltd
is 11.83 CNY
.
Shareholder Return
Price
Henan Lingrui Pharmaceutical Co Ltd
| Average Annual Return | 23.69% |
| Standard Deviation of Annual Returns | 54.7% |
| Max Drawdown | -14% |
| Market Capitalization | 14.2B CNY |
| Shares Outstanding | 555 967 595 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Henan Lingrui Pharmaceutical Co Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Henan Lingrui Pharmaceutical Co., Ltd. engages in the production and sale of medicine and health products. The company is headquartered in Xinyang, Henan and currently employs 2,500 full-time employees. The company went IPO on 2000-10-18. The firm's products include emplastrum, tablets, capsules, ointments and others, applied in the treatment of diabetes mellitus, osteoarthritis, gastropathy, cardiovascular and cerebrovascular diseases, respiratory disease, gynecopathy and dermatopathy, among others. The firm distributes its products throughout China, with Henan Province and Beijing as its major markets.
Contact
IPO
Employees
Officers
The intrinsic value of one
Henan Lingrui Pharmaceutical Co Ltd
stock under the Base Case scenario is
21.28
CNY.
Compared to the current market price of 25.45 CNY,
Henan Lingrui Pharmaceutical Co Ltd
is
Overvalued by 16%.
You don't have any saved screeners yet
